World Lung 2025 – backing for Bristol’s pivotal HER3 conjugate moves
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
World Lung 2025 – Candel looks to a new agla-vec use
But results come from a curated dataset, with no in-trial comparator.
Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
FDA red and green lights: August 2025
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
World Lung 2025 – Summit's Harmoni guessing game
Investors now have more reasons to doubt Harmoni's ability to back US approval.
MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
